Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 35152726)

  • 1. CD19 or CD20 CAR T Cell Therapy Demonstrates Durable Antitumor Efficacy in Patients with Central Nervous System Lymphoma.
    Liu R; Cheng Q; Kang L; Wang E; Li Y; Zhang J; Xiao H; Zhang Y; Chu L; Chen X; Zhang C; Tan J; Xu N; Li M; Yu L; Li X
    Hum Gene Ther; 2022 Mar; 33(5-6):318-329. PubMed ID: 35152726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
    Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
    Front Immunol; 2020; 11():564099. PubMed ID: 33329526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
    Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
    Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma.
    Wu J; Meng F; Cao Y; Zhang Y; Zhu X; Wang N; Wang J; Huang L; Zhou J; Xiao Y
    Blood Cancer J; 2021 Jul; 11(7):131. PubMed ID: 34267187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma.
    Zhang H; Yan Z; Wang Y; Qi Y; Hu Y; Li P; Cao J; Zhang M; Xiao X; Shi M; Xia J; Ma S; Qiao J; Li H; Pan B; Qi K; Cheng H; Sun H; Zhu F; Sang W; Li D; Li Z; Zheng J; Zhao M; Liang A; Huang H; Xu K
    Front Immunol; 2022; 13():965224. PubMed ID: 36059496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review.
    Du J; Zhang Y
    J Cancer Res Clin Oncol; 2020 Jun; 146(6):1575-1582. PubMed ID: 32222815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety-related factors of BTK inhibitors as a bridge to CAR-T therapy in R/R FL.
    Ye X; Fan X; Cui R; Mu J; Liu M; Lyu C; Li Y; Chen L; Zhang J; Li X; Wang J; Mou N; Deng Q
    Ann Hematol; 2023 Jul; 102(7):1789-1799. PubMed ID: 37171599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loop CD20/CD19 CAR-T cells eradicate B-cell malignancies efficiently.
    Chen Z; Liu Y; Chen N; Xing H; Tian Z; Tang K; Rao Q; Xu Y; Wang Y; Wang M; Wang J
    Sci China Life Sci; 2023 Apr; 66(4):754-770. PubMed ID: 36251156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of canine CD20 chimeric antigen receptor T cell manufacturing and in vitro cytotoxic activity against B-cell lymphoma.
    Sakai O; Igase M; Mizuno T
    Vet Comp Oncol; 2020 Dec; 18(4):739-752. PubMed ID: 32329214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma.
    Liu Y; Deng B; Hu B; Zhang W; Zhu Q; Liu Y; Wang S; Zhang P; Yang Y; Yang J; Zheng Q; Yu X; Gao Z; Zhou C; Han W; Yang J; Jin L; Tong C; Chang AH; Zhang Y
    Blood Adv; 2022 Feb; 6(3):717-730. PubMed ID: 34521107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (CAR) construct targeting CD19 and CD20 in the Sleeping Beauty (SB) transposon system.
    Khaniya A; Rad SMAH; Halpin J; Tawinwung S; McLellan A; Suppipat K; Hirankarn N
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38677881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
    Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
    J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL.
    Qi Y; Zhao M; Hu Y; Wang Y; Li P; Cao J; Shi M; Tan J; Zhang M; Xiao X; Xia J; Ma S; Qiao J; Yan Z; Li H; Pan B; Sang W; Li D; Li Z; Zhou J; Huang H; Liang A; Zheng J; Xu K
    Blood; 2022 Jun; 139(23):3376-3386. PubMed ID: 35338773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells.
    Karschnia P; Arrillaga-Romany IC; Eichler A; Forst DA; Gerstner E; Jordan JT; Ly I; Plotkin SR; Wang N; Martinez-Lage M; Winter SF; Tonn JC; Rejeski K; von Baumgarten L; Cahill DP; Nahed BV; Shankar GM; Abramson JS; Barnes JA; El-Jawahri A; Hochberg EP; Johnson PC; Soumerai JD; Takvorian RW; Chen YB; Frigault MJ; Dietrich J
    Neuro Oncol; 2023 Dec; 25(12):2239-2249. PubMed ID: 37402650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma.
    Wang X; Huynh C; Urak R; Weng L; Walter M; Lim L; Vyas V; Chang WC; Aguilar B; Brito A; Sarkissian A; Bandara NA; Yang L; Wang J; Wu X; Zhang J; Priceman SJ; Qin H; Kwak LW; Budde LE; Thomas SH; Clark MC; Popplewell L; Siddiqi T; Brown CE; Forman SJ
    Cancer Immunol Res; 2021 Jan; 9(1):75-88. PubMed ID: 33093217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma.
    Larson SM; Walthers CM; Ji B; Ghafouri SN; Naparstek J; Trent J; Chen JM; Roshandell M; Harris C; Khericha M; Schweppe T; Berent-Maoz B; Gosliner SB; Almaktari A; Ceja MA; Allen-Auerbach MS; Said J; Nawaly K; Mead M; de Vos S; Young PA; Oliai C; Schiller GJ; Timmerman JM; Ribas A; Chen YY
    Cancer Discov; 2023 Mar; 13(3):580-597. PubMed ID: 36416874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma].
    Xiao X; Jiang YY; Cao YQ; Li Q; Jin X; Meng JX; Sui T; Li YM; Zhao MF
    Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):276-280. PubMed ID: 31104437
    [No Abstract]   [Full Text] [Related]  

  • 18. CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease.
    Lu W; Wei Y; Cao Y; Xiao X; Li Q; Lyu H; Jiang Y; Zhang H; Li X; Jiang Y; Meng J; Yuan T; Zhu H; He X; Jin X; Sun R; Sui T; Liu K; Zhao M
    Cancer Immunol Immunother; 2021 Dec; 70(12):3501-3511. PubMed ID: 33899130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignancies.
    Zurko JC; Xu H; Chaney K; Schneider D; Szabo A; Hari P; Johnson BD; Shah NN
    Cytotherapy; 2022 Aug; 24(8):767-773. PubMed ID: 35597752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
    Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
    Front Immunol; 2021; 12():755549. PubMed ID: 34777367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.